Fractyl Health sinks 52% as Revita lawsuits pile up
Alpha Vantage · www.timothysykes.com · · AI-summarised by FinFlash
Fractyl Health (GUTS) shares have fallen more than 52% amid fallout from its Revita clinical trial. Multiple securities class actions allege the company overstated Revita's efficacy and commercial prospects by misrepresenting early trial data, concealing issues at a study site until six-month results showed unexpected weight regain. That disclosure triggered a major Wall Street downgrade.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.